An observational study in Placental Thickness and PLACENTA VOLUME, sponsored by Radia Atef Elzokm. Not yet recruiting. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Radia Atef Elzokm · Observational
The aim of this study is to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.
The placenta is a vital organ that ensures normal fetal growth and development throughout pregnancy by mediating the exchange of oxygen, nutrients, waste products, and essential hormones between the mother and the fetus (1). Any structural or functional abnormality of the placenta can adversely affect fetal growth and pregnancy outcome, highlighting the importance of placental assessment in antenatal care (2).
Adverse pregnancy outcomes, including intrauterine growth restriction (IUGR), preterm birth, low birth weight, preeclampsia, fetal distress, and perinatal mortality, remain major contributors to maternal and neonatal morbidity and mortality worldwide. Early identification of high-risk pregnancies allows timely interventions, closer surveillance, and improved perinatal outcomes (3). However, advances in ultrasonography and antenatal care, reliable, non-invasive, and easily measurable predictors of adverse outcomes are still limited (4).
Ultrasonographic evaluation of placental morphology has emerged as a practical, non-invasive, and widely accessible method to assess placental health. Among the various parameters, placental thickness reflects placental growth, maturation, and potentially its functional capacity, correlating with gestational age and fetal weight in normal pregnancies. Abnormal placental thickness either decreased or increased has been associated with maternal and fetal pathological conditions (5).
A thin placenta is frequently linked to preeclampsia, IUGR, and chorioamnionitis, whereas a thick placenta defined as more than 3 cm before 20 weeks of gestation and greater than 5 cm at term is observed in Rh-negative pregnancies, gestational diabetes mellitus, and intrauterine infections, particularly primary maternal cytomegalovirus infection (6). Placentomegaly may also be associated with fetal anemia or hromosomal abnormalities such as triploidy, and may result from inflammation, edema, or compensatory hypertrophy secondary to placental insufficiency (7).
Maternal disorders often affect both the fetus and the placenta, making abnormal placental growth a potential marker for impaired fetal growth and adverse neonatal outcomes. Nevertheless, the predictive value of placental thickness alone remains uncertain (8).
Given its simplicity, reproducibility, and cost-effectiveness, ultrasonographic measurement of placental thickness and particularly the placental thickness-to-fetal weight ratio may provide a valuable tool for early detection of high-risk pregnancies. This could allow obstetricians to implement timely interventions, optimize delivery planning, and improve maternal and neonatal outcomes (9). Therefore, this study aims to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.
This is the only study on the registry with Radia Atef Elzokm as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Hospital
Exclusion Criteria:
The rate of occurrence of adverse pregnancy outcomes, including IUGR, preterm birth, low birth weight, fetal distress, NICU admission, or perinatal mortality
Correlation of placental thickness-to-fetal weight ratio with individual adverse pregnancy outcomes
Time frame: From aug 2026 to aug 2029
No study locations are listed for this record.
Plan to share: Undecided
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.